AB Science S.A. (ABscience)

Oncology Corporate Profile

HQ Location

51 JFK Parkway, First Floor West
Short Hills, NJ 7078

Company Description

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicine in the United States and Europe. It focuses on therapies for the treatment of cancer, inflammatory diseases, and nervous system diseases. The company's lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. Masitinib is also in three ongoing Phase III trials for the treatment of various indications in humans. The company was founded in 2001 and is headquartered in Paris, France.

Website: http://www.ab-science.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
masitinib / AB1010multiple tyrosine kinase inhibitor1st line Gastrointestinal Stromal Tumors (GIST)III
masitinib / AB1010multiple tyrosine kinase inhibitor2nd line Gastrointestinal Stromal Tumors (GIST)III
masitinib / AB1010multiple tyrosine kinase inhibitorCastrate Resistant 1st line Prostate cancerIII
masitinib / AB1010multiple tyrosine kinase inhibitorColorectal cancerIII
masitinib / AB1010multiple tyrosine kinase inhibitorMelanomaIII
masitinib / AB1010multiple tyrosine kinase inhibitorPancreatic cancerIII
masitinib / AB1010multiple tyrosine kinase inhibitorRelapsed metastatic Ovarian cancerIII
masitinib / AB1010multiple tyrosine kinase inhibitorT-cell lymphomaIII

View additional information on product candidates here »

Source: http://www.ab-science.com/

Recent News Headlines

There are no news items to display